(Q50034027)

23 February 2018

title

Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi. (English)

1 reference

23 February 2018

0 references

0 references

7

1 reference

23 February 2018

author name string

F Micoli

1

1 reference

23 February 2018

S Rondini

2

1 reference

23 February 2018

I Pisoni

3

1 reference

23 February 2018

C Giannelli

4

1 reference

23 February 2018

V Di Cioccio

5

1 reference

23 February 2018

P Costantino

6

1 reference

23 February 2018

L B Martin

8

1 reference

23 February 2018

language of work or name

English

0 references

publication date

13 December 2011

1 reference

23 February 2018

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

23 February 2018

volume

30

1 reference

23 February 2018

issue

5

1 reference

23 February 2018

page(s)

853-861

1 reference

23 February 2018

Global trends in typhoid and paratyphoid Fever

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Typhoid fever in children aged less than 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Bacteremic typhoid fever in children in an urban slum, Bangladesh

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Typhoid fever in children: some epidemiological considerations from Karachi, Pakistan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Protective activity of Vi capsular polysaccharide vaccine against typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Use and validation of an NMR test for the identity and O-acetyl content of the Salmonella typhi Vi capsular polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Liquid chromatographic determination of dicarboxylic acids based on intramolecular excimer-forming fluorescence derivatization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Comparative effects of carrier proteins on vaccine-induced immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

Relation between structure and immunologic properties of the Vi capsular polysaccharide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.108

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.11.108

1 reference

23 February 2018

PubMed ID

22172503

1 reference

23 February 2018